KRAS Inhibitor

Leading KRAS Inhibitor Candidate for Patients with Lung & Colon Cancer, MRTX849 Producing Positive Data in Phase I Trial

Nov 2, 2019 | Cancer, Colorectal Cancer, KRAS, KRAS Inhibitor, Non-Small Cell Lung Cancer, NSCLC, Oncology

In a Phase 1/2 trial MRTX849, an investigational KRAS G12C inhibitor has demonstrated clinical activity, including objective responses in patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). Although a maximum targeted dose has not yet been...

TRIALSITE NEWS IS THE ONLY DIGITAL MEDIA DEDICATED 100% TO TRANSPARENT AND OPEN COVERAGE OF CLINICAL RESEARCH TRIAL SITES AROUND THE GLOBE. BASED IN THE SILICON SLOPES IN DOWNTOWN SALT LAKE CITY, UTAH, WE ARE FOUNDED BY A TEAM OF EXPERTS IN THE CLINICAL TRIALS INDUSTRY AND DEDICATED TO TRANSPARENCY, QUALITY AND CLINICAL TRIAL INNOVATION.

159 WEST BROADWAY SUITE 200
SALT LAKE CITY, UT 84101

Leading KRAS Inhibitor Candidate for Patients with Lung & Colon Cancer, MRTX849 Producing Positive Data in Phase I Trial

Pin It on Pinterest